Decreased expression of SIRT6 promotes tumor cell growth correlates closely with poor prognosis of ovarian cancer

Introduction: Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. If the spread is not controlled, it can result in death. Sirtunins belong to a protein family and it is present in all organisms. SIRT6 is downregulated in tumor and acts as tumor suppressor. These sirtunin proteins are linked to repair DNA and metabolism. Material and Methods: To measure the role of SIRT6 in tumor cell, 20 mice were used and European Collection of Cell Cultures (ECACC) cell lines were used for the analysis. A histopathological technique showed the level of tumor cells. Results: A recent study provided exceptional insight into the mechanism of SIRT6-related chromatin regulation. According to the histopathology of cancer, SIRT1 localizes to the promoters of several aberrantly silenced tumor suppressor genes whose DNA is hypermethylated. SIRT1 has a role associated with the epigenetic hallmarks of cancer. Conclusion: The link between SIRT6 and cancer provide new insight into the therapeutic potential of small molecule activators or specific targets of SIRT6 for the prevention and treatment of cancer. Further investigation into the specific mechanism of SIRT6 is required to realize this potential.

Ovarian cancer; SIRT6 expression; Sirtunins.

[1] Rine, J. N. Strathern, J. B. Hicks, Herskowitz I.: “A suppressor ofmating- type locus mutations in Saccharomyces cerevisiae: evidence for and identification of cryptic matingtype loci,” Genetics, 1979, 93, 877.

[2] Albani, L. Polito, G. Forloni: “Sirtuins as novel targets for Alzheimer’s disease and other neurodegenerative disorders: experimental and genetic evidence”. J. Alzheimers Dis., 2010, 19, 11.

[3] Esteves A.R., Lu J., Rodova M., Onyango I., Lezi E., Dubinsky R., Lyons K.E., et al.: “Mitochondrial respiration and respiration-associated proteins in cell lines created through Parkinson’s subject mitochondrial transfer” J. Neurochem., 2010, 113, 674.

[4] Schumacker T.: “A tumor suppressor SIRTainty.” Cancer Cell, 2010, 17, 5.

[5] Haigis M.C., Sinclair D.A.: “Mammalian sirtuins: biological insights and disease relevance”. Annu. Rev. Pathol., 2010, 5, 253.

[6] Dali-Youcef N., Lagouge M., Froelich S., Koehl C., Schoonjans K., Auwerx J.: “Sirtuins: the ’magnificent seven’, function, metabolism and longevity”. Ann. Med., 2007, 39, 335.

[7] Qiu X., Brown K.V., Moran Y., Chen D.: “Sirtuin regulation in calo-rie restriction”. Biochim. Biophys. Acta, 2010, 1804, 1576.

[8] Ghosh S., George S., Roy U., Ramachandran D., Kolthur-Seetharam U.: “NAD: a master regulator of transcription”. Biochim. Biophys. Acta, 2010, 1799, 681.

[9] Frye R.A.: “Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins”. Biochem. Biophys. Res. Commun., 2000, 273, 793.

[10] Huang J.Y., Hirschey M.D., Shimazu T., Ho L., Verdin E.: “Evolu-tionarily conserved and nonconserved cellular localizations and func-tions of human SIRT proteins”. Mol. Biol. Cell, 2005, 16, 4623.

[11] Huang M.,Hirschey, T. Shimazu, L.Ho, and E. Verdin, “Mitochon-drial sirtuins”. Biochim. Biophys. Acta, 2010, 1804, 1645.

[12] North B.J., Verdin E.: “Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis”. PLoS One, 2007, 2, e784.

[13] Tanno M., Sakamoto J., Miura T., Shimamoto K., Horio Y.: “Nucle-ocytoplasmic shuttling of the NAD+- dependent histone deacetylase SIRT1”. J. Biol. Chem., 2007, 282, 6823.

[14] Deng C.X.: “SIRT1, is it a tumor promoter or tumor suppressor?” Int. J. Biol. Sci., 2009, 5, 147.

[15] Inoue T., Hiratsuka M., Osaki M., Yamada H., Kishimoto I., Yam-aguchi S., et al.: “SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress”. Oncogene, 2007, 26, 945.

[16] Belenky P., Christensen K.C., Gazzaniga F., Pletnev A.A., Brenner C.: “Nicotinamide riboside and nicotinic acid riboside salvage in fungi and mammals quantitative basis for urh1 and purine nucleoside phospho-rylase function in NAD+ metabolism”. J. Biol. Chem., 2009, 284, 158.

[17] McCord R.A., Michishita E., Hong T., Berber E., Boxer L.D., Kusumoto R., et al.: “SIRT6 stabilizes DNA-dependent protein ki-nase at chromatin for DNA double-strand break repair.” Aging (Al-bany NY), 2009, 1, 109.

[18] Mostoslavsky R., Chua K.F., Lombard D.B., Pang W.W., Fischer M.R., Gellon L., et al.: “Genomic instability and aging-like phenotype in the absence of mammalian SIRT6”. Cell, 2006, 124, 315.

[19] Ma W., Stafford L.J., Li D., Luo J., Li X., Ning G., Liu M.:“GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis”. J. Cell. Biochem., 2007, 100, 1376.

[20] Kamel C., Abrol M., Jardine K., He X., McBurney M.W.: “SirT1failstoaffectp53-mediated biologicalfunctions”. Aging Cell, 2006, 5, 81.

[21] Deng C.X.: “SIRT1, isitatumor promoterortumorsuppressor?” Int. J. Biol. Sci., 2009, 5, 147.

[22] Ashraf N., Zino S., Macintyre A., Kingsmore D., Payne A.P., George W.D., Shiels P.G.: “Alteredsirtuinexpression is associatedwithnodepositive breastcancer:. Br. J. Cancer, 2006, 95, 1056.

[23] Dang C.V.: “MYC on the path to cancer”. Cell, 2012, 149, 22.

[24] DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B.: “The biology of cancer: metabolic reprogramming fuels cell growth and proliferation”. Cell Metab., 2008, 7, 11.